{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:26:08Z","timestamp":1773008768427,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"DOI":"10.2146\/ajhp100434","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T18:49:15Z","timestamp":1316458155000},"page":"1806-1809","source":"Crossref","is-referenced-by-count":27,"title":["Use of uridine triacetate for the management of fluorouracil overdose"],"prefix":"10.1093","volume":"68","author":[{"given":"Margaret","family":"McEvilly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Popelas","sequence":"additional","affiliation":[{"name":"BayHealth Medical Center, Dover, DE."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob","family":"Tremmel","sequence":"additional","affiliation":[{"name":"Wellstat Therapeutics Corporation, Gaithersburg, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041106052321100_b1-0681806","first-page":"1404","article-title":"Antineoplastic agents. Chap. 52","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"Chabner","year":"2001","edition":"10th ed"},{"key":"key\n\t\t\t\t2019041106052321100_b2-0681806","first-page":"1067","article-title":"Antineoplastic agents. Chap. 10.00","volume-title":"AHFS drug information 2010","author":"McEvoy","year":"2010"},{"key":"key\n\t\t\t\t2019041106052321100_b3-0681806","first-page":"2095","article-title":"Cancer treatment and chemotherapy. Chap. 130","volume-title":"Pharmacotherapy: a pathophysiological approach","author":"Medina","year":"2008","edition":"7th ed"},{"key":"key\n\t\t\t\t2019041106052321100_b4-0681806","volume-title":"Fluorouracil incident root cause analysis","year":"2007"},{"key":"key\n\t\t\t\t2019041106052321100_b5-0681806","volume-title":"Fluorouracil incident root cause analysis: follow-up","year":"2007"},{"issue":"suppl","key":"key\n\t\t\t\t2019041106052321100_b6-0681806","first-page":"15s","article-title":"Vistonuridine: an orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose","volume":"27","author":"Von Borstel","year":"2009","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041106052321100_b7-0681806","unstructured":"Fox A Howland M . Vistonuridine: a novel antidote for 5-fluorouracil. www.upstate.edu\/poison\/pdf\/tox_newsletter\/01_10toxnews.pdf (accessed 2011 Jun 27)."},{"key":"key\n\t\t\t\t2019041106052321100_b8-0681806","unstructured":"Wellstat Therapeutics Corporation, personal communication, 2010May."},{"key":"key\n\t\t\t\t2019041106052321100_b9-0681806","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00280-005-0129-x","article-title":"5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice","volume":"58","author":"Saif","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"key\n\t\t\t\t2019041106052321100_b10-0681806","first-page":"3964","article-title":"High-dose 5-fluorouracil with delayed uridine \u201crescue\u201d in mice","volume":"42","author":"Martin","year":"1982","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t2019041106052321100_b11-0681806","first-page":"3182","article-title":"Use of uridine rescue to enhance the antitumor selectivity of 5- fluorouracil","volume":"43","author":"Klubes","year":"1983","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t2019041106052321100_b12-0681806","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/bjc.1988.56","article-title":"In vitro biochemical and in vivo biological studies of the uridine \u2018rescue\u2019 of 5- fluorouracil","volume":"57","author":"Peters","year":"1988","journal-title":"Br J Cancer."},{"key":"key\n\t\t\t\t2019041106052321100_b13-0681806","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-4684-1248-2_19","article-title":"Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine","volume":"195","author":"Peters","year":"1986","journal-title":"Adv Exp Med Biol."},{"key":"key\n\t\t\t\t2019041106052321100_b14-0681806","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1016\/0006-2952(92)90142-6","article-title":"Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA","volume":"43","author":"Nord","year":"1992","journal-title":"Biochem Pharmacol."},{"key":"key\n\t\t\t\t2019041106052321100_b15-0681806","first-page":"5928","article-title":"Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity","volume":"44","author":"Leyva","year":"1984","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t2019041106052321100_b16-0681806","first-page":"745","article-title":"Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity","volume":"70","author":"Van Groeningen","year":"1986","journal-title":"Cancer Treat Rep."},{"key":"key\n\t\t\t\t2019041106052321100_b17-0681806","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/0006-2952(96)00102-5","article-title":"5-(m-benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2\u2032,3\u2032,5\u2032-tri-O- acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy","volume":"51","author":"Ashour","year":"1996","journal-title":"Biochem Pharmacol."},{"key":"key\n\t\t\t\t2019041106052321100_b18-0681806","unstructured":"Wellstat Therapeutics Corporation, personal communication, 2010May."},{"key":"key\n\t\t\t\t2019041106052321100_b19-0681806","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicology and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol."},{"key":"key\n\t\t\t\t2019041106052321100_b20-0681806","unstructured":"National Institutes of Health. Public teleconference regarding licensing and collaborative research opportunities for: methods and compositions relating to detecting dihydropyrimidine dehydrogenase (DPD). www.federalregister.gov\/articles\/2008\/07\/03\/E8-15182\/public-teleconference-regarding-licensing-and-collaborative-research-opportunities-for-methods-and (accessed 2011 Jun 6)."},{"key":"key\n\t\t\t\t2019041106052321100_b21-0681806","unstructured":"Tremmel R , Wellstat Therapeutics Corporation, personal communication, 2010May."},{"key":"key\n\t\t\t\t2019041106052321100_b22-0681806","article-title":"Uridine triacetate: an investigational orally administered, life-saving antidote for 5FU overdose","author":"Bamat"},{"key":"key\n\t\t\t\t2019041106052321100_b23-0681806","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00254098","article-title":"Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine","volume":"24","author":"Martin","year":"1989","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/19\/1806\/28350146\/ajhp1806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T00:15:53Z","timestamp":1560644153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/19\/1806\/5129397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100434","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,10,1]]},"published":{"date-parts":[[2011,10,1]]}}}